SCHEMBL19743038

SCHEMBL19743038

Nc1c(S(=O)(=O)c2ccccc2)c2nccnc2n1C1CCCCC1O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
GAA P10253 3/20 0.49
FFAR2 O15552 15/20 0.40
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
DNMT1 P26358 1/20 0.38
BLM P54132 1/20 0.38
PLEC Q15149 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CASP1 P29466 1/20 0.36
RAB9A P51151 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19742980 0.87 KDM4E (0.49) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL17378947 0.85 KDM4E (0.61) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19742984 0.84 KDM4E (0.62) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19743007 0.81 KDM4E (0.47) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19743004 0.81 KDM4E (0.47) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19742991 0.78 KDM4E (0.52) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19743026 0.77 KDM4E (0.56) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL19743042 0.76 KDM4E (0.46) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL17378989 0.75 KDM4E (0.48) KDM4EALDH1A1GAAFFAR2KMT2A
SCHEMBL17378999 0.74 KDM4E (0.47) KDM4EALDH1A1GAAFFAR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US claimed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE TAKEDA PHARMACEUTICALS CO (JP) 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369492-A1 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE GPR119, IDO1, IDO2 KDM4E 556/4885ALDH1A1 1063/4885GAA 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.